Abstract
Epidermal growth factor receptor (EGFR) mutations are the most common among non-small cell lung cancer (NSCLC), with available target treatment with tyrosine-kinase inhibitor (TKI) as first-line on advanced disease. The aim of this study was to evaluate the demographic characteristics of patients with advanced NSCLC EGFR mutated, treatments performed and outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
